|
Market Closed -
Nasdaq
01:30:00 05/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 28.02 USD | +0.57% |
|
-3.74% | +4.90% |
| 25/08 | Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating | MT |
| 25/08 | EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu | MT |
| Market Cap | 482.8Cr 415.45Cr 390.88Cr 357.07Cr 667.97Cr 46TCr 669.79Cr 4.62TCr 1.79TCr 23TCr 1.81TCr 1.77TCr 75TCr | P/E 2026 * |
46.3x | P/E 2027 * | 32.6x |
|---|---|---|---|---|---|
| Enterprise Value | 381.9Cr 328.63Cr 309.19Cr 282.45Cr 528.38Cr 36TCr 529.82Cr 3.65TCr 1.42TCr 19TCr 1.43TCr 1.4TCr 60TCr | EV / Sales 2026 * |
3x | EV / Sales 2027 * | 2.51x |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ACAD | Delayed | |
CBOE
| ACAD | Real-time | |
|
Mexican S.E.
| ACAD * | End-of-day quote | |
|
Tradegate
| DR6 | Real-time | |
|
Deutsche Boerse AG
| DR6 | Delayed | |
|
Börse Stuttgart
| DR6 | Delayed | |
|
Boerse Muenchen
| DR6 | Real-time |
Last Transcript : ACADIA Pharmaceuticals Inc.
| 1 day | +0.57% | ||
| 1 week | -3.74% | ||
| Current month | -3.08% | ||
| 1 month | -1.51% | ||
| 3 months | +29.96% | ||
| 6 months | +26.44% | ||
| Current year | +4.90% |
| 1 week | 27.62 |  | 29.75 |
| 1 month | 27.62 | | 30.96 |
| Current year | 19.89 | | 30.96 |
| 1 year | 19.69 | | 30.96 |
| 3 years | 13.4 | | 32.59 |
| 5 years | 12.24 | | 33.99 |
| 10 years | 12.24 | | 58.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Catherine Adams
CEO | Chief Executive Officer | 55 | 20/09/2024 |
Mark Schneyer
DFI | Director of Finance/CFO | 52 | 10/09/2021 |
Scott Cenci
CTO | Chief Tech/Sci/R&D Officer | - | 04/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Laura Brege
BRD | Director/Board Member | 68 | 01/05/2008 |
Stephen Biggar
CHM | Chairman | 55 | 10/06/2016 |
Edmund Harrigan
BRD | Director/Board Member | 73 | 25/11/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/08/26 | Exercice | Chief Financial Officer | 42,876 | 0.0250% | ||
| 30/07/26 | Sell | Chief Technology Officer | -16,558 | 0.0097% | ||
| 29/05/26 | Exercice | Director | 41,529 | 0.0243% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.57% | -3.74% | +10.93% | +3.36% | 482.8Cr | |
| -1.23% | -3.09% | -2.00% | +13.48% | 4.89TCr | |
| -0.40% | +1.03% | +418.57% | +527.30% | 4.5TCr | |
| -1.42% | +2.30% | +42.67% | +22.37% | 4.41TCr | |
| -1.22% | -2.31% | +4.82% | +77.49% | 4.07TCr | |
| +0.53% | -1.36% | +16.87% | +46.82% | 3.35TCr | |
| -0.21% | +9.14% | - | - | 1.78TCr | |
| -0.35% | -1.56% | +21.42% | +120.75% | 1.65TCr | |
| -1.49% | -1.24% | +12.08% | +31.21% | 1.47TCr | |
| -1.65% | -1.03% | +75.93% | +41.12% | 1.38TCr | |
| Average | -0.69% | +0.11% | +66.81% | +98.21% | 2.8TCr | |
| Weighted average by Cap. | -0.80% | +0.04% | +87.83% | +126.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 127.27Cr 109.51Cr 103.04Cr 94Cr 176.08Cr 12TCr 176.55Cr 1.22TCr 472.46Cr 6.16TCr 477.89Cr 467.47Cr 20TCr | 143.32Cr 123.32Cr 116.03Cr 105.99Cr 198.28Cr 14TCr 198.82Cr 1.37TCr 532.05Cr 6.94TCr 538.17Cr 526.43Cr 22TCr |
| Net income | 11Cr 9.08Cr 8.55Cr 7.81Cr 15Cr 996.76Cr 15Cr 101Cr 39Cr 511.4Cr 40Cr 39Cr 1.65TCr | 16Cr 13Cr 13Cr 12Cr 22Cr 1.48TCr 22Cr 149.63Cr 58Cr 757.65Cr 59Cr 57Cr 2.44TCr |
| Net Debt | -100.9Cr -87Cr -82Cr -75Cr -139.59Cr -9.53TCr -139.97Cr -965.26Cr -374.56Cr -4.89TCr -378.87Cr -370.61Cr -16TCr | -123.71Cr -106.45Cr -100.15Cr -91Cr -171.15Cr -12TCr -171.62Cr -1.18TCr -459.25Cr -5.99TCr -464.53Cr -454.4Cr -19TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | $28.02 | +0.57% | 16,82,950 |
| 03/26/03 | $27.86 | -3.70% | 18,49,411 |
| 02/26/02 | $28.93 | +0.14% | 15,55,986 |
| 01/26/01 | $28.89 | -0.07% | 8,30,928 |
| 31/26/31 | $28.91 | -0.69% | 10,35,961 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACAD Stock
Select your edition
All financial news and data tailored to specific country editions
